Agents of Change: Improving the Collaboration Among CAR T Center Experts and Community-Based Clinicians for Improved Care of DLBCL Patients

Target Professions: DO, MD, Nurse Practitioner, Pharmacist, Physician Assistant, Nurse, Pharmacy Director
Target Specialties: Hematology, Hematology/Oncology, Oncology
Credits Available: 4.25 AMA PRA Category 1 Credits™, 4.25 ANCC Contact Hours, 4.25 ACPE

This dynamic curriculum, detailed by a specialty center clinician, explores each of the CD 19-directed CAR T-cell therapies available for the treatment of DLBCL; solutions to referral and logistic challenges; in-depth early and late toxicity management in CAR T-cell treatment; and the delivery of goal-concordant care using shared decision-making strategies. A challenging real-world case scenario discussion within each Gather-ed group highlights critical decision points, key challenges, and opportunities to incorporate collective insights.


CME/CE Accreditation Information

Itinerary

Part 1

Agents of Change: Improving the Collaboration Among CAR T Center Experts and Community-Based Clinicians for Improved Care of DLBCL Patients - Baseline Assessment

This assessment will provide a baseline measure of your knowledge of CAR T-cell therapy and management for DLBCL, including, barriers, and challenges for treatment.

Module 1 - Lisocabtagene maraleucel (liso-cel)

Lisocabtagene maraleucel safety and efficacy data

Module 2: Axicabtagene ciloleucel (axi-cel)

Axicabtagene ciloleucel safety and efficacy data

Module 3: Tisagenlecleucel (tisa-cel)

Tisagenlecleucel (tisa-cel) safety and efficacy data

Module 4: Eligibility, referral, and barriers

Eligibility, logistics, and barriers to early referral for CAR T-cell therapy

Module 5: Adverse event management post-CAR T treatment

Lisocabtagene maraleucel safety and efficacy data

Module 6: Shared clinician-patient decision-making when considering CAR T-cell therapy

Shared clinician-patient decision-making when considering CAR T-cell therapy

Agents of Change: Improving the Collaboration Among CAR T Center Experts and Community-Based Clinicians for Improved Care of DLBCL Patients - Final Assessment

This assessment will provide a measure of knowledge and competence gained from completion of the study modules.

Live Group Discussion 1

Join your group colleagues to discuss the program curriculum, including a review of the foundational videos. Bring your key questions and discussion points to engage in a robust conversation related to CAR T-cell therapy for DLBCL.

Part 2

Patient Case - Group Challenge - Mr. R, a 62-year-old male

This is the story of Mr. R, who will undergo CAR T-cell therapy. Review each section of the case and respond to your challenge assignments.

Your Action Plan In CAR T-cell Therapy for DLBCL

In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the early referral and complex management of your patients with DLBCL.

Live Group Discussion 2

Join your group colleagues to discuss the case scenario, including your management recommendations, and challenges identified.

Interested in becoming a Group Leader?

Requirements:
Group leaders are CAR T-specialized center hematologists or hematologist-oncologists who have extensive experience specifically with CAR T management for patients with DLBCL, and who care for these patients in specialized CAR T centers (and therefore meet REMS criteria). Apply Now

Interested in participating in this curriculum? You can join one of the following groups:

NG
Natalie Grover, MD
Associate Professor
Enroll
Swetha Kambhampati, MD
Assistant Professor
Enroll
JK
Jean Koff, MD
Associate Professor
Enroll
Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Enroll
Matthew Lunning, DO
Associate Professor
Enroll
Reem Karmali, MD, MS

Enroll
Reem Karmali, MD, MS

Enroll